Galena Biopharma (GALE) Misses Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Galena Biopharma Reports Second Quarter 2014 Results
August 11, 2014 4:35 PM EDTAbstral® (fentanyl) sublingual tablet net revenue was $2.3 million in Q2 2014 and $4.5 million in 1H 2014. U.S. license of Zuplenz® (ondansetron) oral soluble film expands portfolio to two commercial products. On track to reach two significant milestones in 2H 2014: completing enrollment activities in the NeuVax (nelipepimut-S) Phase 3 PRESENT study in breast cancer, and initiating the Phase 2 clinical trial with GALE-401 (anagrelide CR) in essential thrombocythemia.
PORTLAND, Ore., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet... More
